Review





Similar Products

il 8  (Bioss)
94
Bioss il 8
Il 8, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 8/product/Bioss
Average 94 stars, based on 1 article reviews
il 8 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc il 8
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Il 8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 8/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
il 8 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology antibodies against il 8
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Antibodies Against Il 8, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against il 8/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
antibodies against il 8 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology anti interleukin il 8
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Anti Interleukin Il 8, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti interleukin il 8/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
anti interleukin il 8 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc anti cxcl8 cat
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Anti Cxcl8 Cat, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cxcl8 cat/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
anti cxcl8 cat - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

95
Proteintech anti cxcl8
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Anti Cxcl8, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cxcl8/product/Proteintech
Average 95 stars, based on 1 article reviews
anti cxcl8 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology anti il 8
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Anti Il 8, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti il 8/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
anti il 8 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

95
Proteintech anti il 8
LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators <t>IL-6,</t> <t>IL-8</t> , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.
Anti Il 8, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti il 8/product/Proteintech
Average 95 stars, based on 1 article reviews
anti il 8 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators IL-6, IL-8 , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.

Journal: International Dental Journal

Article Title: NLRP12 Alleviated Periodontal Destruction via Suppressing Nuclear Factor Kappa-B Signalling Pathway

doi: 10.1016/j.identj.2026.109417

Figure Lengend Snippet: LPS triggered an inflammatory response and suppressed the osteogenic differentiation potential of PDLSCs. (A) The proliferative capacity of PDLSCs exposed to varying LPS concentrations over 2, 4, and 6 days was measured with CCK-8 assay. (B) The qRT-PCR analysis revealed elevated mRNA expression of inflammatory mediators IL-6, IL-8 , and IL-10 in PDLSCs following treatment with 10 µg/mL LPS. The qRT-PCR (C) and WB (D) analysis revealed significantly lower expression of osteogenic markers (COL1 and RUNX2) in PDLSCs exposed to 10 µg/mL LPS. The ALP (E) and alizarin red (F) staining assays showed that 10 µg/mL LPS significantly inhibited the osteogenic differentiation capacity of PDLSCs compared to the control group. Data were presented as mean ± SD ( n = 3). *** P < .001, **** P < .0001.

Article Snippet: After blocking with 10% normal goat serum (Beyotime), sections were covered overnight at 4°C with primary antibodies against IL-6 (#21865-1-AP; Proteintech), IL-8 (#94407; CST), IL-10 (#ab290735; Abcam), COL1 (#12256; CST) and RUNX2 (#8486; CST), then covered with secondary antibodies Goat Anti-Rabbit IgG (Zsbio), and then stained with DAB (Zsbio) for 20 to 60 seconds and counterstained with haematoxylin.

Techniques: CCK-8 Assay, Quantitative RT-PCR, Expressing, Staining, Control

NLRP12 overexpression reduced LPS-induced inflammatory response and reversed LPS-induced suppression of osteogenic differentiation in PDLSCs. (A and B) The qRT-PCR and WB data revealed that expression level of NLRP12 in oeNLRP12 group was increased significantly compared to oeNC group. (C) The qRT-PCR data revealed that mRNA expression of IL-6 and IL-8 was suppressed, while the mRNA expression of IL-10 was increased in oeNLRP12 + LPS group compared to oeNC + LPS group. (D) The expression of COL1 and RUNX2 was increased significantly detected by WB assays in oeNLRP12 + LPS group compared to oeNC + LPS group. (E) Representative pictures of ALP staining showed lower staining in oeNC + LPS group compared to oeNC group and higher staining in oeNLRP12 + LPS group compared to oeNC + LPS group (scale bar = 500 μm). (F) Representative pictures of alizarin red staining showed fewer mineralized nodules in oeNC + LPS group compared to oeNC group and more mineralized nodules in oeNLRP12 + LPS group compared to oeNC + LPS group (scale bar = 500 μm). oeNC: PDLSCs transfected via negative control lentiviral. oeNLRP12: PDLSCs transfected via lentiviral with overexpression- NLRP12 . oeNC + LPS: PDLSCs transfected via negative control lentiviral and subsequently cultured under 10 µg/mL LPS induction. oeNLRP12 + LPS: PDLSCs transfected via lentiviral with overexpression- NLRP12 and subsequently cultured under 10 µg/mL LPS induction. Data were presented as mean ± SD ( n = 3). ns, no significant difference, *** P < .001, **** P < .0001.

Journal: International Dental Journal

Article Title: NLRP12 Alleviated Periodontal Destruction via Suppressing Nuclear Factor Kappa-B Signalling Pathway

doi: 10.1016/j.identj.2026.109417

Figure Lengend Snippet: NLRP12 overexpression reduced LPS-induced inflammatory response and reversed LPS-induced suppression of osteogenic differentiation in PDLSCs. (A and B) The qRT-PCR and WB data revealed that expression level of NLRP12 in oeNLRP12 group was increased significantly compared to oeNC group. (C) The qRT-PCR data revealed that mRNA expression of IL-6 and IL-8 was suppressed, while the mRNA expression of IL-10 was increased in oeNLRP12 + LPS group compared to oeNC + LPS group. (D) The expression of COL1 and RUNX2 was increased significantly detected by WB assays in oeNLRP12 + LPS group compared to oeNC + LPS group. (E) Representative pictures of ALP staining showed lower staining in oeNC + LPS group compared to oeNC group and higher staining in oeNLRP12 + LPS group compared to oeNC + LPS group (scale bar = 500 μm). (F) Representative pictures of alizarin red staining showed fewer mineralized nodules in oeNC + LPS group compared to oeNC group and more mineralized nodules in oeNLRP12 + LPS group compared to oeNC + LPS group (scale bar = 500 μm). oeNC: PDLSCs transfected via negative control lentiviral. oeNLRP12: PDLSCs transfected via lentiviral with overexpression- NLRP12 . oeNC + LPS: PDLSCs transfected via negative control lentiviral and subsequently cultured under 10 µg/mL LPS induction. oeNLRP12 + LPS: PDLSCs transfected via lentiviral with overexpression- NLRP12 and subsequently cultured under 10 µg/mL LPS induction. Data were presented as mean ± SD ( n = 3). ns, no significant difference, *** P < .001, **** P < .0001.

Article Snippet: After blocking with 10% normal goat serum (Beyotime), sections were covered overnight at 4°C with primary antibodies against IL-6 (#21865-1-AP; Proteintech), IL-8 (#94407; CST), IL-10 (#ab290735; Abcam), COL1 (#12256; CST) and RUNX2 (#8486; CST), then covered with secondary antibodies Goat Anti-Rabbit IgG (Zsbio), and then stained with DAB (Zsbio) for 20 to 60 seconds and counterstained with haematoxylin.

Techniques: Over Expression, Quantitative RT-PCR, Expressing, Staining, Transfection, Negative Control, Cell Culture

Overexpression of NLRP12 alleviated the inflammatory responses and osteogenic differentiation inhibition of PDLSCs by suppressing the NF-κB pathway. (A) WB results showing the changes of protein expression levels of p-p65, p65, p-IκBα, and IκBα in PDLSCs after NLRP12 overexpression. (B) WB results showing the changes of protein expression levels of p-p65 and p65 in PDLSCs overexpressing NLRP12 after PMA treatment. (C)The qRT-PCR results demonstrating the transcriptional expression levels of IL-6, IL-8 , and IL-10 in PDLSCs overexpressing NLRP12 after PMA treatment. (D)WB results demonstrating alterations in the protein expression levels of COL1 and RUNX2 in PDLSCs overexpressing NLRP12 after PMA treatment. (E) Representative pictures showing ALP staining (scale bar = 500 μm) (F) Representative pictures showing alizarin red staining (scale bar = 500 μm). oeNC: PDLSCs transfected via negative control lentiviral. oeNLRP12: PDLSCs transfected via lentiviral with overexpression- NLRP12 . oeNC + LPS: PDLSCs transfected via negative control lentiviral and subsequently cultured under 10 µg/mL LPS. oeNLRP12 + LPS: PDLSCs transfected via lentiviral with overexpression- NLRP12 and subsequently cultured under 10 µg/mL LPS. Data were presented as mean ± SD ( n = 3). ns, no significant difference, * P < .05, ** P < .01, *** P < .001, **** P < .0001.

Journal: International Dental Journal

Article Title: NLRP12 Alleviated Periodontal Destruction via Suppressing Nuclear Factor Kappa-B Signalling Pathway

doi: 10.1016/j.identj.2026.109417

Figure Lengend Snippet: Overexpression of NLRP12 alleviated the inflammatory responses and osteogenic differentiation inhibition of PDLSCs by suppressing the NF-κB pathway. (A) WB results showing the changes of protein expression levels of p-p65, p65, p-IκBα, and IκBα in PDLSCs after NLRP12 overexpression. (B) WB results showing the changes of protein expression levels of p-p65 and p65 in PDLSCs overexpressing NLRP12 after PMA treatment. (C)The qRT-PCR results demonstrating the transcriptional expression levels of IL-6, IL-8 , and IL-10 in PDLSCs overexpressing NLRP12 after PMA treatment. (D)WB results demonstrating alterations in the protein expression levels of COL1 and RUNX2 in PDLSCs overexpressing NLRP12 after PMA treatment. (E) Representative pictures showing ALP staining (scale bar = 500 μm) (F) Representative pictures showing alizarin red staining (scale bar = 500 μm). oeNC: PDLSCs transfected via negative control lentiviral. oeNLRP12: PDLSCs transfected via lentiviral with overexpression- NLRP12 . oeNC + LPS: PDLSCs transfected via negative control lentiviral and subsequently cultured under 10 µg/mL LPS. oeNLRP12 + LPS: PDLSCs transfected via lentiviral with overexpression- NLRP12 and subsequently cultured under 10 µg/mL LPS. Data were presented as mean ± SD ( n = 3). ns, no significant difference, * P < .05, ** P < .01, *** P < .001, **** P < .0001.

Article Snippet: After blocking with 10% normal goat serum (Beyotime), sections were covered overnight at 4°C with primary antibodies against IL-6 (#21865-1-AP; Proteintech), IL-8 (#94407; CST), IL-10 (#ab290735; Abcam), COL1 (#12256; CST) and RUNX2 (#8486; CST), then covered with secondary antibodies Goat Anti-Rabbit IgG (Zsbio), and then stained with DAB (Zsbio) for 20 to 60 seconds and counterstained with haematoxylin.

Techniques: Over Expression, Inhibition, Expressing, Quantitative RT-PCR, Staining, Transfection, Negative Control, Cell Culture

Overexpression of NLRP12 in PDLSCs alleviated the inflammatory responses and promoted periodontal regeneration in periodontitis rats. (A) The timeline demonstrated the experimental procedures. (B) The micro-CT scanning results. (C) Representative images of H&E staining (the black scale bars and white scale bars are 200 and 100 μm, respectively). (D) Representative images of Masson trichrome staining (the black scale bars and white scale bars are 200 and 100 μm, respectively). (E) Cementoenamel junction (CEJ)–alveolar bone crest (ABC) distance. (F) bone volume/total volume (BV/TV). (G) Loss of attachment in H&E staining. (H) Semiquantitative analysis of Masson trichrome staining. (I) Representative immunohistochemical images showing the expression level of inflammatory factor IL-6, IL-8, and IL-10, osteogenic factor COL1, and RUNX2, and TRAP staining showing the number of osteoclasts. Scale bar = 100 μm. (J) Quantitative analysis of IL-6-positive cells, IL-8-positive cells, IL-10-positive cells, COL1-positive cells, and RUNX2-positive cells. (K) Quantitative result of TRAP+ cells. Control group: without treatment. Periodontitis group: ligature-induced experimental periodontitis model. oeNC group: periodontitis group treated with oeNC PDLSCs. oeNLRP12 group: periodontitis group treated with oeNLRP12 PDLSCs. IHC: immunohistochemistry. IOD, integrated option density. The data are presented as mean ± SD ( n = 6 rats per group). *P < .1 , **P < .01 , ***P < .001 , ****P < .0001 .

Journal: International Dental Journal

Article Title: NLRP12 Alleviated Periodontal Destruction via Suppressing Nuclear Factor Kappa-B Signalling Pathway

doi: 10.1016/j.identj.2026.109417

Figure Lengend Snippet: Overexpression of NLRP12 in PDLSCs alleviated the inflammatory responses and promoted periodontal regeneration in periodontitis rats. (A) The timeline demonstrated the experimental procedures. (B) The micro-CT scanning results. (C) Representative images of H&E staining (the black scale bars and white scale bars are 200 and 100 μm, respectively). (D) Representative images of Masson trichrome staining (the black scale bars and white scale bars are 200 and 100 μm, respectively). (E) Cementoenamel junction (CEJ)–alveolar bone crest (ABC) distance. (F) bone volume/total volume (BV/TV). (G) Loss of attachment in H&E staining. (H) Semiquantitative analysis of Masson trichrome staining. (I) Representative immunohistochemical images showing the expression level of inflammatory factor IL-6, IL-8, and IL-10, osteogenic factor COL1, and RUNX2, and TRAP staining showing the number of osteoclasts. Scale bar = 100 μm. (J) Quantitative analysis of IL-6-positive cells, IL-8-positive cells, IL-10-positive cells, COL1-positive cells, and RUNX2-positive cells. (K) Quantitative result of TRAP+ cells. Control group: without treatment. Periodontitis group: ligature-induced experimental periodontitis model. oeNC group: periodontitis group treated with oeNC PDLSCs. oeNLRP12 group: periodontitis group treated with oeNLRP12 PDLSCs. IHC: immunohistochemistry. IOD, integrated option density. The data are presented as mean ± SD ( n = 6 rats per group). *P < .1 , **P < .01 , ***P < .001 , ****P < .0001 .

Article Snippet: After blocking with 10% normal goat serum (Beyotime), sections were covered overnight at 4°C with primary antibodies against IL-6 (#21865-1-AP; Proteintech), IL-8 (#94407; CST), IL-10 (#ab290735; Abcam), COL1 (#12256; CST) and RUNX2 (#8486; CST), then covered with secondary antibodies Goat Anti-Rabbit IgG (Zsbio), and then stained with DAB (Zsbio) for 20 to 60 seconds and counterstained with haematoxylin.

Techniques: Over Expression, Micro-CT, Staining, Immunohistochemical staining, Expressing, Control, Immunohistochemistry